100 lbs lost on GLP-1s: what the science says about results like this

What's this video probably claiming?

Based on the caption and hashtags, this creator is documenting a 100-pound weight loss over approximately 18 months, attributing her results to a combination of GLP-1 receptor agonist therapy through Mochi Health, lifestyle habit changes, and working with a fitness coach. The referral code in the caption suggests she may be an affiliate or brand partner, which is worth keeping in mind when evaluating the framing. The #mochihealth tag specifically ties this to a telehealth platform prescribing medications like semaglutide or tirzepatide. The overall message appears to be that GLP-1 therapy, when paired with behavioral coaching and gym work, can produce dramatic, sustained weight loss. That's a reasonable thing to say. But 100 lbs in 18 months is on the higher end of what clinical trials show, and the way these transformations get packaged on TikTok often strips out the harder, messier parts of the story that matter for anyone considering the same path.

What does the science actually show?

The clinical data on GLP-1 medications is genuinely impressive, but it comes with context that rarely makes it into a 60-second video. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide at 15mg produced mean weight loss of 20.9% of body weight over 72 weeks in people with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg achieved 14.9% mean body weight reduction over 68 weeks. A 100-pound loss would require a starting weight around 500 lbs at the 20% figure, or substantial deviation from average response. That doesn't mean it's impossible. Individual response varies considerably, and pairing medication with structured exercise and dietary coaching likely amplifies outcomes. But the "average" patient is not losing 100 lbs. Presenting outlier results as typical, even implicitly, skews what new patients expect from treatment.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and clinical reality is the attribution problem. When someone loses 100 pounds, how much came from the medication, how much from coaching, how much from dietary changes, and how much from the psychological shift that comes with committing to a program? Trials like SURMOUNT-1 controlled for lifestyle intervention, but real-world patients are doing all of these simultaneously. The other issue is discontinuation. The STEP 4 trial (Rubino et al., 2021, JAMA) found that patients who stopped semaglutide regained two-thirds of their lost weight within a year. That finding almost never appears in transformation content. Affiliate codes also create a financial incentive structure that makes balanced storytelling harder. None of that means this creator's results are fake or her experience is invalid. It means the content format selects for the best-case framing, and viewers are rarely getting a complete picture of what long-term GLP-1 use actually looks like.

What should you actually know?

If you're considering a GLP-1 program through a telehealth platform, here's what the data actually supports. First, these medications work, and for many people they work significantly better than any prior intervention. Second, results are highly variable. The patients in the top quartile of clinical trials do lose considerably more weight than the average, and lifestyle factors genuinely do appear to modify outcomes. A 2023 analysis in Obesity (Wadden et al.) found that adding structured behavioral intervention to semaglutide improved weight loss outcomes beyond medication alone. Third, the mechanism is not purely appetite suppression. GLP-1 receptors are distributed across multiple organ systems and the research on cardiovascular benefits, specifically the SELECT trial (Lincoff et al., 2023, NEJM) showing 20% reduction in major cardiovascular events with semaglutide, suggests these are not simply diet pills. Fourth, compounded semaglutide and brand-name Wegovy or Ozempic are not the same product, and the FDA has raised concerns about compounded versions. Any telehealth platform worth using should be transparent about what they're prescribing and why.